Clinical Trials Browser

Phase 2 × Smoldering Multiple Myeloma × daratumumab × Clear all

NCT03236428 2026-03-27

Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma

Phase 2 Active not recruiting

42 enrolled 8 charts

Smoldering Multiple Myeloma, Paraproteinemias

NCT02316106 2025-04-27

A Study to Evaluate 3 Dose Schedules of Daratumumab in Participants With Smoldering Multiple Myeloma

Phase 2 Completed

Smoldering Multiple Myeloma, Multiple Myeloma

NCT03289299 2023-12-12

ASCENT

Phase 2 Active not recruiting

Smoldering Multiple Myeloma, Neoplasms, Plasma Cell